Biogenesis of ribosomes make an interesting target for cancer chemotherapy for many reasons: (1) the inhibition of ribosome biogenesis induces cell cycle arrest in a p53-independent manner [63], (2) these inhibitions don’t affect the resting cells, possibly due to the long half-life of cytoplasmic ribosomes [64], and (3) it could lead to apoptosis of neoplastic cells that have a high nucleolar ribosomal biogenesis rate [65]. Here, TP53 is linked to cancer.